Quote: "The apparent freeze on new trials bothers me."
It shouldn't bother you if you can see the big picture.
You see, if Anavex were to start new trials for Fragile X, Angelman Syndrome, or any other disease before Rett approval, they would have to spend millions of dollars and add years of research conducting P1, P2 and P3 trials for each disease.
However if the FDA approves A2-73 for Rett, Anavex can repurpose the drug and simply run one P3 trial for each disease.
So yes, there is a freeze...but there's a good reason for it.
See the big picture and relax.